Come join others currently navigating treatment in our weekly Virtual Support Groups! See times and register here.
We've made it easier for you to connect! Fill out your NEW profile.
Breastcancer.org is hiring! Read the job posting: Virtual Support Group Facilitator and Community Moderator
Diagnosed Young? We'd love your answers to these questions.
Take our poll: What's one thing your body is teaching you this summer?
Podcast: AIs vs. Tamoxifen for Pre-Menopausal Early-Stage, HR+
Options
moderators
Posts: 9,295
December 13, 2021
Dr. Jeremy Braybrooke, is a consultant medical oncologist and clinical lead for oncology at University Hospitals Bristol, as well as a senior clinical research fellow at the University of Oxford. Rosie Bradley is a medical statistician in the Clinical Trial Service Unit at the University of Oxford.
At the 2021 San Antonio Breast Cancer Symposium, Rosie presented the results of their meta-analysis of four studies looking at effectiveness of aromatase inhibitors compared to tamoxifen in pre-menopausal women diagnosed with early-stage, hormone receptor-positive disease.
Listen to the episode to hear them explain:
- the results of the study, showing that an aromatase inhibitor and ovarian suppression reduced recurrence risk more than tamoxifen, but didn't lead to better overall survival
- the side effects of aromatase inhibitors and tamoxifen
- how Dr. Braybrooke is advising his pre-menopausal patients diagnosed with early-stage, hormone receptor-positive disease
Running time: 14:19
Listen now or read the transcript.0
Categories
Join Us on Zoom: Upcoming virtual support groups. Read more...
Share more about you! Fill out your NEW profile.
Breastcancer.org is hiring! Read the job posting: Virtual Support Group Facilitator and Community Moderator